Skip to main content

Table 1 Dose-response of etoricoxib for lack of efficacy and clinical adverse event discontinuations in osteoarthritis and rheumatoid arthritis trials

From: Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports

Dose etoriocoxib (mg)

Number of patients

Discontinuations (%)

  

Lack of efficacy

Clinical adverse event

Osteoarthritis

   

   0

974

16

5.2

   30

1015

7.3

4.1

   60

814

3.6

4.8

   90

112

1.8

5.4

   120

221

0.9

7.7

Rheumatoid arthritis

   

   0

1,143

29

2.7

   60

126

1.6

4.8

   90

913

14

2.7

   120

463

3.9

5.4